Open-angle Glaucoma, Visual Field
Conditions
Keywords
Citicoline, Gingko biloba, magnesium, Open-angle Glaucoma, visual field, MEMOPTIC
Brief summary
Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients. The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.
Interventions
DRUGMEMOPTIC
Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
DRUGusual treatment of glaucoma
Patients will receive only their usual treatment of glaucoma.
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects * age between 20 and 80 years old * Well controled intra-ocular pressure under treatment (PIO\<21mmHg or decreased by 20% compared to initial the PIO)
Exclusion criteria
* retinal or macular disease * diagnosis of cataract or surgery of cataract during the follow-up * allergy to citicolin * ocular hypertonia due to a secondary cause (like corticosteroids) * history of anterior, intermediate or posterior uveitis * general treatment affecting PIO (beta blockers, corticosteroids) * pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation of visual field of open angle-glaucoma patients with MEMOPTIC treatment | from day 0 to 2 years | Variation of visual field of open angle-glaucoma patients with MEMOPTIC treatment versus visual field of open angle-glaucoma patients without MEMOPTIC treatment. Visual field is measure with METROVISION Visual Field 24-2, a full field projection perimeter entirely compatible with the Goldmann standard and modern perimetry standard. It allows high resolution static perimetry as well as kinetic perimetry with automated and manual modes. Automated static perimetry is one of the methods used to screen and follow up patients who have glaucoma. It consists of approximately 100 quantitative threshold measures that permit evaluation of retinal sensitivity. Each measure is standardized in a population free of ocular disease, and two simple statistics are calculated: mean deviation (MD) and pattern standard deviation (PSD). These indices are widely used in glaucoma clinical trials and patient follow-up. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORClaire Iscar, MD
CHU Amiens
Outcome results
None listed